Acadia Pharmaceuticals Income Statement (2010-2025) | ACAD

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Revenue & cost
Revenue (Quarter)	106.55M	115.22M	131.61M	130.76M	115.47M	134.56M	130.71M	136.49M	118.46M	165.24M	211.70M	231.04M	205.83M	241.96M	250.40M	259.60M	244.32M	264.57M	278.63M	283.99M
Cost of Revenue (Quarter)	2.19M	2.53M	3.69M	10.74M	2.95M	2.67M	2.14M	2.41M	1.67M	7.46M	14.62M	17.89M	22.95M	18.23M	18.86M	21.80M	20.39M	20.73M	21.65M	26.23M
Gross Profit (Quarter)	104.37M	112.69M	127.92M	120.02M	112.52M	131.90M	128.58M	134.08M	116.80M	157.78M	197.08M	213.15M	182.88M	223.73M	231.54M	237.80M	223.93M	243.83M	256.99M	257.76M
Operating items
Research & Development (Quarter)	56.97M	56.94M	58.56M	66.94M	128.85M	75.65M	81.34M	75.74M	69.14M	58.77M	156.96M	66.74M	59.68M	76.23M	66.61M	100.73M	78.27M	77.95M	87.83M	84.76M
Selling, General & Administrative (Quarter)	111.66M	96.79M	81.67M	105.91M	96.68M	89.90M	78.11M	104.40M	101.23M	95.97M	97.89M	111.47M	107.99M	117.06M	133.29M	130.08M	126.37M	133.51M	133.40M	155.62M
Other Operating Expenses (Quarter)	4.69M	5.21M	6.68M	2.56M	2.95M	2.67M	2.14M	2.41M	1.67M	7.46M	14.62M	17.89M	22.95M	18.23M	18.86M	-124.71M	20.39M	20.73M	21.65M	26.23M
Operating Expenses (Quarter)	173.33M	158.93M	146.91M	175.41M	228.48M	168.21M	161.58M	182.55M	172.05M	162.20M	269.48M	196.10M	190.62M	211.53M	218.76M	106.10M	225.03M	232.19M	242.88M	266.60M
Operating Income (Quarter)	-66.77M	-43.71M	-15.30M	90.60M	-113.02M	-33.65M	-30.87M	132.71M	-53.58M	3.04M	-57.78M	34.94M	15.21M	30.44M	31.64M	153.50M	19.29M	32.37M	35.76M	-58.11M
EBIT (Quarter)	-66.77M	-43.71M	-15.30M	90.60M	-113.02M	-33.65M	-30.87M	132.71M	-53.58M	3.04M	-57.78M	34.94M	15.21M	30.44M	31.64M	153.50M	19.29M	32.37M	35.76M	-58.11M
Non-operating items
Interest & Investment Income (Quarter)	0.20M	0.13M	0.13M	0.13M	0.10M	0.58M	2.29M	3.63M	3.80M	4.55M	4.12M	4.76M	5.51M	6.36M	6.59M	7.01M	7.90M	7.24M	8.25M	8.33M
Other Non Operating Income (Quarter)	-0.14M	0.18M	0.38M	1.62M	0.34M	-0.50M	2.16M	1.54M	4.84M	-1.24M	1.51M		0.29M	0.39M	0.58M	0.57M	0.59M	0.59M	0.59M	0.60M
Non Operating Income (Quarter)	-0.14M	0.18M	0.38M	1.62M	0.34M	-0.50M	2.16M	-3.97M	4.84M	-1.24M	1.51M	-10.19M	0.29M	0.39M	0.58M	-14.96M	0.59M	0.59M	0.59M	0.60M
Net income details
EBT (Quarter)	-66.43M	-43.40M	-14.79M	-42.91M	-112.57M	-33.60M	-26.41M	-40.84M	-44.94M	6.30M	-52.14M	39.66M	21.00M	37.18M	38.81M	161.07M	27.80M	40.20M	44.60M	26.32M
Tax Provisions (Quarter)	0.02M	0.47M	-0.33M	0.19M	0.48M	0.44M	0.80M	0.83M	-1.90M	5.20M	13.03M	-6.05M	4.40M	3.79M	6.04M	17.32M	8.80M	13.54M	-27.18M	3.08M
Profit After Tax (Quarter)	-66.45M	-43.87M	-14.46M	-43.09M	-113.06M	-34.01M	-27.18M	-41.73M	-43.02M	1.11M	-65.18M	45.80M	16.55M	33.39M	32.77M	143.74M	18.99M	26.67M	71.78M	273.57M
Income from Continuing Operations (Quarter)	-66.45M	-43.87M	-14.46M	-43.09M	-113.06M	-34.04M	-27.21M	-41.68M	-43.04M	1.10M	-65.18M	45.71M	16.60M	33.39M	32.77M	143.75M	19.00M	26.66M	71.78M	23.24M
Consolidated Net Income (Quarter)	-66.45M	-43.87M	-14.46M	-43.09M	-113.06M	-34.04M	-27.21M	-41.68M	-43.04M	1.10M	-65.18M	45.71M	16.60M	33.39M	32.77M	143.75M	19.00M	26.66M	71.78M	23.24M
Income towards Parent Company (Quarter)	-66.45M	-43.87M	-14.46M	-43.09M	-113.06M	-34.04M	-27.21M	-41.68M	-43.04M	1.10M	-65.18M	45.71M	16.60M	33.39M	32.77M	143.75M	19.00M	26.66M	71.78M	23.24M
Net Income towards Common Stockholders (Quarter)	-66.45M	-43.87M	-14.46M	-43.09M	-113.06M	-34.04M	-27.21M	-41.68M	-43.02M	1.11M	-65.18M	45.80M	16.55M	33.39M	32.77M	143.74M	18.99M	26.67M	71.78M	273.57M
Additional items
EPS (Basic) (Quarter)	-0.42	-0.27	-0.09	-0.27	-0.70	-0.21	-0.17	-0.26	-0.27	0.01	-0.40	0.28	0.10	0.20	0.20	0.87	0.11	0.16	0.43	1.62
EPS (Weighted Average and Diluted) (Quarter)	-0.42	-0.27	-0.09	-0.27	-0.70	-0.21	-0.17	-0.26	-0.27	0.01	-0.40	0.28	0.10	0.20	0.20	0.86	0.11	0.16	0.42	1.61
Shares Outstanding (Weighted Average) (Quarter)	160.01M	0.16M	0.16M	0.16M	161.23M	0.16M	0.16M	161.68M	162.26M	163.46M	163.49M	163.82M	164.80M	0.17M	165.97M	165.72M	166.81M	167.83M	168.84M	168.36M
Shares Outstanding (Diluted Average) (Quarter)		0.16M	0.16M	0.16M	161.23M	0.16M	0.16M	161.68M	162.26M	165.05M	164.23M	163.82M	166.62M	166.17M	166.14M	166.36M	167.67M	0.17M	170.65M	169.92M
EBITDA (Quarter)	-66.77M	-43.71M	-15.30M	90.60M	-113.02M	-33.65M	-30.87M	132.71M	-53.58M	3.04M	-57.78M	34.94M	15.21M	30.44M	31.64M	153.50M	19.29M	32.37M	35.76M	-58.11M
Interest Expenses (Quarter)
Tax Rate (Quarter)	-0.03%	-1.09%	2.24%	-0.44%	-0.43%	-1.32%	-3.03%	-2.04%	4.23%	82.54%	-24.99%	-15.25%	20.95%	10.20%	15.57%	10.76%	31.65%	33.69%	-60.95%	11.68%

Research Tools

Acadia Pharmaceuticals Income Statement (2010-2025) | ACAD

Create an account

Sign In

Reset Password